Amyris Exceeds Previous Debt Reduction Goal of $75 Million – $86 Million In Debt Retired
May 22, 2017 12:35 pm UTC| Business
EMERYVILLE, Calif., May 22, 2017 -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced it has already exceeded the debt reduction goal the company stated in its May 8, 2017 announcements...
Amyris Exceeds Previous Debt Reduction Goal of $75 Million – $86 Million In Debt Retired
May 22, 2017 12:35 pm UTC| Business
EMERYVILLE, Calif., May 22, 2017 -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced it has already exceeded the debt reduction goal the company stated in its May 8, 2017 announcements...
Amyris Exceeds Previous Debt Reduction Goal of $75 Million – $86 Million In Debt Retired
May 22, 2017 12:35 pm UTC| Business
EMERYVILLE, Calif., May 22, 2017 -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced it has already exceeded the debt reduction goal the company stated in its May 8, 2017 announcements...
Amyris Exceeds Previous Debt Reduction Goal of $75 Million – $86 Million In Debt Retired
May 22, 2017 12:35 pm UTC| Business
EMERYVILLE, Calif., May 22, 2017 -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced it has already exceeded the debt reduction goal the company stated in its May 8, 2017 announcements...
Amyris Exceeds Previous Debt Reduction Goal of $75 Million – $86 Million In Debt Retired
May 22, 2017 12:35 pm UTC| Business
EMERYVILLE, Calif., May 22, 2017 -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced it has already exceeded the debt reduction goal the company stated in its May 8, 2017 announcements...
May 22, 2017 12:35 pm UTC| Business
NEW YORK, May 22, 2017 -- Tyme Technologies, Inc. (OTCQB:TYMI), a clinical stage biotechnology company developing cancer therapeutics to address multiple tumor types, today announced that it will present data from its...
May 22, 2017 12:35 pm UTC| Business
NEW YORK, May 22, 2017 -- Tyme Technologies, Inc. (OTCQB:TYMI), a clinical stage biotechnology company developing cancer therapeutics to address multiple tumor types, today announced that it will present data from its...